Review ArticleR
Open Access
Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia
MICHAEL MEDINGER, CLAUDIA LENGERKE and JAKOB PASSWEG
Cancer Genomics & Proteomics September 2016, 13 (5) 317-329;
MICHAEL MEDINGER
1Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland
2Division of Internal Medicine, Department of Medicine, University Hospital Basel, Basel, Switzerland
CLAUDIA LENGERKE
1Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland
JAKOB PASSWEG
1Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland
In this issue
Cancer Genomics & Proteomics
Vol. 13, Issue 5
September-October 2016
Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia
MICHAEL MEDINGER, CLAUDIA LENGERKE, JAKOB PASSWEG
Cancer Genomics & Proteomics Sep 2016, 13 (5) 317-329;
Jump to section
- Article
- Abstract
- Prognosis/Risk Stratification
- Standard Therapy for AML
- New Mutations with Prognostic and Therapeutic Implications in AML
- Fms-like Tyrosine Kinase 3 (FLT3) Mutations
- Nucleophosmin 1 (NPM1) Mutations
- DNA Methyltansferase 3A (DNMT3A) Mutations
- IDH Mutations
- TET2 Mutations
- Runt-Related Transcription Factor (RUNX1) Mutations
- CCAAT Enhancer Binding Protein α (CEBPA) Mutations
- Additional Sex Comb-like 1 (ASXL1) Mutations
- MLL Mutations
- Tumor Protein p53 (TP53) Mutations
- c-KIT Mutations
- Novel Targets and Drugs
- Conclusion
- Footnotes
- References
- Figures & Data
- Info & Metrics
Related Articles
- No related articles found.
Cited By...
- Determination of Cuproptosis-related Subtypes, Development of a Prognostic Model, and Characterization of Tumor Microenvironment Infiltration in Acute Myeloid Leukemia
- Prognostic value of an eighteen-genes panel in acute myeloid leukemia by analyzing TARGET and TCGA databases
- Molecular Genetic Characterization of Acute Myeloid Leukemia With Trisomy 4 as the Sole Chromosome Abnormality